Microsoft WordDabigatran Boehringer-Ingelheim PSD FINAL.docx

First Page		Document Content
Date: 2014-10-01 21:56:23 Hematology Direct thrombin inhibitors Anticoagulants Bristol-Myers Squibb Dabigatran Warfarin Apixaban Stroke Rivaroxaban Chemistry Organic chemistry Medicine		Microsoft WordDabigatran Boehringer-Ingelheim PSD FINAL.docx Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 166,34 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qfnw - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv DocID: 1p0MX - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Novel Oral Anticoagulant (NOAC) for Atrial Fibrillation (AF) Pharmaceutical Services Department o DocID: 1kWDd - View Document
	SPECIAL AUTHORIZATION REQUEST Dabigatran(Pradaxa®), Rivaroxaban(Xarelto®), Apixaban(Eliquis®) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – DocID: 1g5ry - View Document
	DecemberSTROKE PREVENTION IN ATRIAL FIBRILLATION: ROLE OF THE NEWER ORAL ANTICOAGULANTS DocID: 1g4kh - View Document